Table 3.
Yield and sensitivity of EUS-FNA for diagnosing intrapulmonary tumors located near or adjacent to the esophagus
| Study [Ref.], year | Type of study | Total EUS performed, n | Total with any malignancy, n (%) | Tumor visualized by EUS, n (%) | Adequate tissue sample by EUS-FNA, n (%) | Correct diagnosis by EUS-FNA, n | Correct diagnosis of any malignancy by EUS-FNA, n | Yield for correct diagnosisb (95% CI) | Sensitivity for malignancyc (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| Varadarajulu [19], 2004a | Retrospective | 18 | 18 (100) | 18 (100) | 18 (100) | 18 | 18 | 1.00 (0.69 – 1.00) | 1.00 (0.69 – 1.00) |
| Annema [20], 2005 | Prospective | 32 | 32 (100) | 32 (100) | 31 (97) | 31 | 31 | 0.97 (0.81 – 1.00) | 0.97 (0.81 – 1.00) |
| Paquin [21], 2005a | Retrospective | 15 | 13 (87) | 15 (100) | 15 (100) | 14 | 12 | 0.93 (0.65 – 0.99) | 0.92 (0.61 – 0.99) |
| Sawhney [22], 2006 | Prospective | 19 | 18 (95) | 16 (84) | 16 (84) | 13 | 12 | 0.68 (0.45 – 0.85) | 0.67 (0.43 – 0.84) |
| Hernandez [23], 2007a | Retrospective | 17 | 17 (100) | 17 (100) | 17 (100) | 17 | 17 | 1.00 (0.68 – 1.00) | 1.00 (0.68 – 1.00) |
| Nguyen [24], 2011 | Retrospective | 24 | NR | 24 (100) | 24 (100) | 23 | NR | 0.96 (0.76 – 0.99) | – |
| Songür [25], 2011a | Prospective | 22 | 20 (91) | 22 (100) | 17 (77) | 16 | 16 | 0.73 (0.51 – 0.87) | 0.80 (0.57 – 0.92) |
| Assisi [26], 2013a | Retrospective | 11 | 11 (100) | 11 (100) | 11 (100) | 11 | 11 | 1.00 (0.58 – 1.00) | 1.00 (0.58 – 1.00) |
| Vazquez-Sequeiros [27], 2013 | Retrospective | 73 | NR | 62 (85) | 61 (84) | 60 | NR | 0.82 (0.72 – 0.89) | – |
| Nasir [28], 2014 | Retrospective | 55 | 55 (100) | 55 (100) | 52 (95) | 52 | 52 | 0.95 (0.84 – 0.98) | 0.95 (0.84 – 0.98) |
| Steinfort [29], 2016a | Retrospective | 27 | 27 (100) | 27 (100) | 27 (100) | 26 | 26 | 0.96 (0.78 – 0.99) | 0.96 (0.78 – 0.99) |
NR, not reported; EUS-FNA, endoscopic ultrasound-guided fine-needle aspiration.
Unclear whether EUS had been able to visualize the tumor in all patients included, or whether the patients in whom this was not possible were excluded from the analysis.
Yield was calculated as the number of patients in whom EUS-FNA made a correct biopsy-proven diagnosis (nonmalignant or malignant) divided by the total number of patients in whom EUS was performed with the aim of diagnosing an intrapulmonary tumor.
Sensitivity was calculated as the number of patients in whom EUS-FNA made a correct biopsy-proven diagnosis of a malignancy divided by the total number of patients in whom the targeted intrapulmonary tumor turned out to be malignant.